Fundamental Analysis of CERVOMED INC(NASDAQ:CRVO) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to CRVO. CRVO was compared to 568 industry peers in the Biotechnology industry. CRVO has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CRVO is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CRVO has reported negative net income.

In the past year CRVO has reported a negative cash flow from operations.

In the past 5 years CRVO always reported negative net income.

CRVO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CRVO has a Return On Assets of -24.44%. This is in the better half of the industry: CRVO outperforms 73.27% of its industry peers.

With an excellent Return On Equity value of -26.18%, CRVO belongs to the best of the industry, outperforming 80.89% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-24.44%
ROE	-26.18%
ROIC	N/A

ROA(3y)-51.44%

ROA(5y)-52.29%

ROE(3y)-58.53%

ROE(5y)-59.85%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for CRVO has been increased compared to 1 year ago.

CRVO has more shares outstanding than it did 5 years ago.

CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRVO has an Altman-Z score of 1.59. This is a bad value and indicates that CRVO is not financially healthy and even has some risk of bankruptcy.

CRVO has a better Altman-Z score (1.59) than 68.85% of its industry peers.

There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1.59

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CRVO has a Current Ratio of 15.04. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 15.04, CRVO belongs to the best of the industry, outperforming 90.44% of the companies in the same industry.

CRVO has a Quick Ratio of 15.04. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CRVO (15.04) is better than 90.44% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.04
Quick Ratio	15.04

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CRVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.87%, which is quite impressive.

Looking at the last year, CRVO shows a very strong growth in Revenue. The Revenue has grown by 116.02%.

EPS 1Y (TTM)66.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%21.43%

Revenue 1Y (TTM)116.02%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%27.13%

3.2 Future

The Earnings Per Share is expected to decrease by -35.84% on average over the next years. This is quite bad

The Revenue is expected to grow by 29.03% on average over the next years. This is a very strong growth

EPS Next Y-19.44%

EPS Next 2Y-36.82%

EPS Next 3Y-35.55%

EPS Next 5Y-35.84%

Revenue Next Year59.7%

Revenue Next 2Y-22.73%

Revenue Next 3Y-25.99%

Revenue Next 5Y29.03%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CRVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CRVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CRVO's earnings are expected to decrease with -35.55% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-36.82%

EPS Next 3Y-35.55%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CRVO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CERVOMED INC

NASDAQ:CRVO (12/18/2024, 4:51:56 PM)

After market: 2.03 +0.03 (+1.5%)

+0.06 (+3.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap16.50M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.44%
ROE	-26.18%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	15.04
Quick Ratio	15.04
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)66.87%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-19.44%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)116.02%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CERVOMED INC (CRVO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens